Afatinib as first-line treatment in patients with
EGFR mutation
afatinib
first-line
non-interventional study
non-small cell lung cancer
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
08
2020
accepted:
01
04
2021
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
18
5
2021
Statut:
epublish
Résumé
Lung cancer is a leading cause of cancer-related death in Germany and worldwide. Non-small cell lung cancer (NSCLC) comprises ~80% of lung cancer diagnoses; in White patients, around 10% of NSCLC cases are epidermal growth factor receptor mutation-positive ( In NCT02047903, a prospective non-interventional study in Germany, patients with Of 152 patients, 106 (69.7%) were female, 20 (13.1%) patients had an uncommon The results support clinical trial data for afatinib in routine clinical practice, including in patients generally excluded from clinical trials. Outcomes were positive in patients with uncommon
Sections du résumé
BACKGROUND
BACKGROUND
Lung cancer is a leading cause of cancer-related death in Germany and worldwide. Non-small cell lung cancer (NSCLC) comprises ~80% of lung cancer diagnoses; in White patients, around 10% of NSCLC cases are epidermal growth factor receptor mutation-positive (
METHODS
METHODS
In NCT02047903, a prospective non-interventional study in Germany, patients with
RESULTS
RESULTS
Of 152 patients, 106 (69.7%) were female, 20 (13.1%) patients had an uncommon
CONCLUSION
CONCLUSIONS
The results support clinical trial data for afatinib in routine clinical practice, including in patients generally excluded from clinical trials. Outcomes were positive in patients with uncommon
Identifiants
pubmed: 33995597
doi: 10.1177/17588359211012361
pii: 10.1177_17588359211012361
pmc: PMC8111535
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17588359211012361Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: This study was supported by Boehringer Ingelheim. Wolfgang Brückl has received honoraria for consulting from AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Chugai, Lilly, MSD, Pfizer, Roche Pharmaceuticals and Takeda. Joachim Ficker has received speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Chugai, GSK, MSD, Novartis, Pfizer, Roche, and Sanofi-Aventis. Frank Griesinger has served on advisory councils or committees for Boehringer Ingelheim, Roche, and AstraZeneca; and has received honoraria, consulting fees, and grants or funds, from Boehringer Ingelheim, Roche, and Astra Zeneca. Stefan Krüger has received honoraria, and grants or funds, from Boehringer Ingelheim. Justyna Rawluk has served on advisory councils or committees for AstraZeneca, BMS, MSD, Boehringer Ingelheim, Roche, and Takeda; and has received consulting fees from AstraZeneca, BMS, MSD, Boehringer Ingelheim, Roche, and Takeda. Martin Reck has served on advisory councils or committees for AbbVie, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Lilly, Merck, MSD, Novartis, Pfizer, Roche, and Sanofi; received speaker honoraria from AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Lilly, Merck, MSD, Novartis, Pfizer, and Roche; and received consulting fees from AbbVie, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Lilly, Merck, MSD, Novartis, Pfizer, Roche, and Sanofi. Christopher Hoffman and Andrea Schüler are employees of Boehringer Ingelheim. Stephan Budweiser, Tobias Gaska, Cornelius Kortsik, Konrad Kokowski, Eckart Laack, and Harold Schäfer have no potential conflicts of interest to declare.
Références
Lung Cancer. 2019 Jan;127:103-111
pubmed: 30642537
JAMA Oncol. 2019 Oct 1;5(10):1448-1455
pubmed: 31393548
Ann Oncol. 2016 Nov;27(11):2103-2110
pubmed: 27601237
Ann Glob Health. 2019 Jan 22;85(1):
pubmed: 30741509
Lancet Oncol. 2014 Feb;15(2):213-22
pubmed: 24439929
Lung Cancer. 2018 Mar;117:14-19
pubmed: 29496250
Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1254-61
pubmed: 26070531
Eur J Cancer. 1994;30A(5):635-42
pubmed: 8080679
Ann Oncol. 2017 Feb 1;28(2):270-277
pubmed: 28426106
Patient. 2018 Feb;11(1):131-141
pubmed: 29178024
Lancet Oncol. 2015 Feb;16(2):141-51
pubmed: 25589191
J Thorac Oncol. 2016 Mar;11(3):380-90
pubmed: 26823294
Oncotarget. 2017 Jun 27;8(57):97602-97612
pubmed: 29228636
Am J Clin Oncol. 2016 Apr;39(2):126-31
pubmed: 24632817
J Clin Oncol. 1998 Jan;16(1):139-44
pubmed: 9440735
Thorac Cancer. 2019 May;10(5):1078-1085
pubmed: 31006178
J Thorac Oncol. 2020 May;15(5):803-815
pubmed: 31931137
Oncotarget. 2017 Jul 26;8(52):90430-90443
pubmed: 29163842
Med Oncol. 2019 May 14;36(6):57
pubmed: 31089973
Lancet Oncol. 2016 May;17(5):577-89
pubmed: 27083334
J Natl Compr Canc Netw. 2013 Feb 1;11(2):161-9
pubmed: 23411383
Acta Oncol. 2017 Mar;56(3):438-440
pubmed: 27892773
Ther Adv Med Oncol. 2019 Apr 15;11:1758835919836374
pubmed: 31019567
BMC Pharmacol Toxicol. 2017 Dec 13;18(1):82
pubmed: 29237484
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Transl Lung Cancer Res. 2019 Jun;8(3):302-316
pubmed: 31367543
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
BMC Cancer. 2019 Sep 9;19(1):896
pubmed: 31500587
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
Lancet Oncol. 2015 Jul;16(7):830-8
pubmed: 26051236
Future Oncol. 2019 Feb;15(6):637-652
pubmed: 30404555
Cancer Treat Rev. 2018 Sep;69:143-151
pubmed: 30014952
Oncologist. 2021 Apr;26(4):281-287
pubmed: 32969527
Clin Lung Cancer. 2018 Jul;19(4):e465-e479
pubmed: 29653820
BMC Cancer. 2018 Dec 3;18(1):1198
pubmed: 30509246
J Thorac Oncol. 2016 Mar;11(3):407-13
pubmed: 26725180